Increase in Inquiries as Companies Accelerate Their Work in Regenerative and Cell Medicine
First written in FY2017-Q1. 14 of 17 entries say "Restated". Latest entry: 2026-08-13.
The whole theme swung hardest in 2025: 1 of 10 companies on the "Worse" side.
0 other companies' latest entry also says "Restated".
- FY2024-Q2RestatedAnnual report
「The Company is focusing on expanding contract manufacturing of specified cell processing products and strengthening the foundation of its CDMO business.」
The Company continues to pursue a policy of expanding the business areas of its cell processing business, including specified cell processing products manufacturing, the CDMO business and the value-chain business. - FY2023-Q3RestatedAnnual report
「In the cell-processing business, we are actively pursuing initiatives to expand its three business areas: specified cellular product manufacturing, the CDMO business and the value-chain business.」
The company continues to pursue expansion in the three areas of specified cellular product manufacturing, the CDMO business and the value-chain business. - FY2022-Q3RestatedAnnual report
「細胞加工業については、細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
特定細胞加工物製造業、バリューチェーン事業、CDMO事業の3領域を拡大する方針を継続している。 - FY2022-Q2RestatedAnnual report
「細胞加工業については、細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
特定細胞加工物製造業、バリューチェーン事業、CDMO事業の3領域を拡大する方針を継続している。 - FY2022-Q1RestatedAnnual report
「細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
The Company continues to pursue a policy of expanding the three areas of its cell processing business. - FY2021-Q3RestatedAnnual report
「細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
The Company continues to pursue a policy of expanding the three areas of its cell processing business. - FY2021-Q2RestatedAnnual report
「細胞加工業については、細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
Against a backdrop of business opportunities in regenerative and cellular medicine, the Company continues to pursue a policy of expanding the three areas of its cell processing business. - FY2021-Q1RestatedAnnual report
「細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
The Company continues to pursue a policy of expanding the three areas of its cell processing business. - FY2020-Q3RestatedAnnual report
「細胞加工業については、細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
The Company continues to describe its efforts to expand the three areas of specified cell processing products manufacturing, the value-chain business and the CDMO business. - FY2019-Q3RestatedAnnual report
「細胞加工業については、細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
特定細胞加工物製造業、バリューチェーン事業、CDMO事業の3領域を拡大する方針を継続している。 - FY2019-Q2RestatedAnnual report
「細胞加工業の３つのビジネス領域（「特定細胞加工物製造業」・「バリューチェーン事業」・「CDMO事業」）の拡大に向けて積極的な活動を展開しております。」
特定細胞加工物製造業、バリューチェーン事業、CDMO事業の3領域を拡大する方針を継続している。 - FY2018-Q2RestatedAnnual report
「During the six-month period ended the second quarter, the Company actively pursued initiatives to expand the three business areas of its cell processing business: specified cell processing products manufacturing, the value-chain business and the CDMO business.」
特定細胞加工物製造業、バリューチェーン事業、CDMO事業の3領域を拡大する方針を継続している。 - FY2017AdvancedAnnual report
「During the consolidated fiscal year, the Company Group viewed these changes in the business environment as business opportunities and actively pursued initiatives to expand its three business areas: the cell processing business, the value-chain business and the CDMO business.」
The Company has moved from describing an increase in inquiries and contracted projects to explicitly identifying the three areas of business development: the cell processing business, the value-chain business and the CDMO business. - FY2017-Q3AdvancedAnnual report
「Regarding net sales, the number of orders received in the value-chain business increased, leading to higher sales from Ibaraki Prefectural Children's Hospital and from facility operations and management services contracted by Juntendo University, among other factors.」
The assessment of the business environment has progressed from an increase in inquiries to an increase in orders received in the value-chain business and the generation of specific contract-service revenue. - FY2017-Q1First statedAnnual report
「Pharmaceutical companies, regional core medical institutions and research institutions that had not previously been active in regenerative and cellular medicine are accelerating their initiatives in these fields, resulting in an increase in inquiries to the Company.」
The business environment is described as one in which pharmaceutical companies, regional core medical institutions and research institutions are accelerating their initiatives, increasing inquiries to the Company.